Latest Conference Articles

Bothnia Dystrophy generally presents during early childhood; patients have night blindness, progressive visual loss, and subsequent legal blindness.

A case series illuminates neuro-ophthalmologic manifestations, retinal vascular involvement and other pathologies

The research team used spectral-domain OCT and OCT angiography imaging to study the changes in the retinal microvasculature in patients

Dr Margaret A. Chang shares data on the port delivery system with ranibizumab, and her strategy for making the most of conferences

Businesses in the retina care space tease new technologies and cutting-edge therapeutics

Focus on collaboration, career development, and innovation

As part of the Barcelona meeting, retina specialists can recognise the awareness day early

In this study, the investigators retrospectively analyzed the incidence of metastasis in 8,034 patients with uveal melanoma over a 35-year period based on tumor size category.

Fasika Woreta, MD, spoke about shattering glass ceilings in ophthalmology, highlighting the importance of diversity, mentorship, and empowering women in leadership roles within the field during her WIO Honorary Lecture and Award.

These 4 women will feature in talks across the WIO Summer Symposium. Together they welcome all attendees to the 2024 meeting in Carlsbad, California.

Nicole Bajic, MD, shared a bit about the skills labs at the Women in Ophthalmology Summer Symposium, the value that this meeting provides, and what she is looking forward to at this event.

Christina Y. Weng, MD, MBA discussed what attendees, both virtually and in-person, can expect from this year's Women in Ophthalmology Summer Symposium meeting in Carlsbad, California. The meeting will take place August 22-25, 2024.

The WIO Summer Symposium offers attendees a chance to network, build practice management skills, and plan to reach new goals and milestones in their career.

Stephanie Marioneaux, MD, gives insight into the inspiration and research discussed in her talk “First in Medicine: An African American perspective from 1700 to 1940" as the Patricia Bath Distinguished Lecture at the National Medical Association's annual conference in New York City, NY.

M. Roy Wilson, MD, touches upon reconceptualizing the use of race in medicine as part of his Robert Copeland Distinguished Lecture at the National Medical Association's annual conference in New York City, NY.

Kathryn Colby, MD, PhD, described diagnosing and managing these tumors at the National Medical Association annual meeting, Ophthalmology Session in New York.

Fasika Woreta, MD, discussed the Roman-Barnes lecture and the cornea care landscape ahead of the National Medical Association meeting.

Ore-ofe O. Adesina, MD, described the advances in diagnostics and therapeutics in Neuro-Ophthalmology at the National Medical Association annual meeting.

Sally S. Ong, MD, spoke with Modern Retina about her research titled, "Individual and neighborhood-level socioeconomic characteristics associated with presenting visual acuity and foveal status in rhegmatogenous retinal detachment" at the annual ASRS meeting in Stockholm, Sweden.

Companies continue to share news about the data that will be presented at the 2024 ASRS meeting in Stockholm, Sweden.

42nd Annual Meeting in Stockholm, the Venice of the North

The ASRS annual meeting will take place in Stockholm, Sweden on July 16-20, 2024. Several major updates are already anticipated at the event.

The award, supported by Oculis, will recognize outstanding contributions to retina research and will grant €30,000 for research support, and an additional €5,000 directly to the candidate.

The 2024 event was held in Seattle, Washington, from May 5 through May 9. Members of the Ophthalmology Times team attended and interviewed several researchers and industry professionals, highlighting news from the meeting.

Anat Loewenstein, MD, spoke with Modern Retina about her presentation of AXPAXLI trial results and upcoming trials for this potential treatment, which she gave at Clinical Trials at the Summit meeting held in Park City, Utah on June 8, 2024.

This retrospective real-world evaluation of the drug considered a number of important as-yet-unanswered questions.

To date, only the onset and enlargement of hyperTDs measured using en-face OCT imaging has been validated as a clinical trial endpoint.

Jennifer Lim, MD, FARVO, spoke with us about her presentation Faricimab vs aflibercept in the reduction of exudates in Y/R trials" at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.